NASDAQ · Financial Statements

Lakewood-Amedex Biotherapeutics Inc. (LABT) Financial Statements

$0.79 NASDAQ: LABT Market Cap $1.39M

Lakewood-Amedex Biotherapeutics Inc. most recently reported annual revenue of $0, net profit of $-4.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Annual Financials (USD)

Metric202320242025
Revenue$0$0$0
Operating Profit$-9.0M$-4.0M$-4.0M
Net Profit$-8.0M$-5.0M$-4.0M
EPS$-11.84$-6.94$-2.76
Op Margin———

Balance Sheet (USD)

Metric202320242025
Total Assets——$0
Total Liabilities——$2.0M
Cash——$0
Borrowings$0$0$2.0M

Cash Flow (USD)

Metric202320242025
Operating Cash Flow——$-2.0M
Investing Cash Flow——$0
Financing Cash Flow——$0
Net Cash Flow——$0
Free Cash Flow$0$0$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.06
FCF Yield-119.23%
Quick Ratio7.70
Interest Coverage-58.40
Return 1Y—
Return 3Y—
Return 5Y—

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
LABT Overview LABT Dividend Run Stock Screener